Recently we reported that human dermal fibroblasts, or conditioned media obtained from such cells, affect the growth of human melanoma cells as a direct function of tumor progression: melanoma cells obtained from earlystage (metastatically incompetent) primary lesions were growth inhibited, whereas cells obtained from more advanced (metastaticaly competent) primary lesions, or metastases, were growth stimulated. Ion-exchange and gel-filtration chromatography of fibroblast conditioned medium revealed the inhibitor to be a protein of molecular mass between 20 and 30 kDa and distinct from the stimulator. This is the approximate molecular mass of interleukin 6 (IL-6), a ubiquitous multifunctional cytokine known to affect in particular many kinds of hemopoietic and lymphoid cells. Since this cytokine is known to be made by fibroblasts, we attempted to determine if the human fibroblast-derived growth inhibitor (hFDGI) was identical to IL-6. Neutralizing antibodies specific for IL-6 completely eliminated the inhibitory activity ofhFDGI. Moreover, exposure to human recombinant IL-6 was found to inhibit the growth of earlystage melanoma cells obtained from radial growth phase (RGP) or early vertical growth phase (VGP) primary lesions in three of four cases. In contrast, melanoma cells from a number of more advanced VGP primary lesions, or from distant metastases, were completely resistant to this IL-6-mediated growth inhibition. Acquisition of an "IL-6-resistant" phenotype by metastatically competent melanoma cell variants may provide such cells with a proliferative advantage within the dermal mesenchyme (a hallmark of melanoma cells that are malignant), helping them eventually to dominate advanced primary lesions and to establish secondary growths elsewhere.
The growth and spread of cancers can be strongly influenced by surrounding normal tissues in a variety of ways. Tumor angiogenesis-i.e., the process satisfying the absolute requirement of new blood vessel capillaries for solid tumors to grow beyond 1-2 mm in diameter-is perhaps the most striking illustration of this interaction (1) . Similarly, a variety of different hormones or locally produced growth factors and cytokines secreted by various normal cells can stimulate tumor growth (2, 3) . In addition to stimulating the growth of tumors, surrounding normal cells can, in other circumstances, significantly suppress such growth (4); this is especially evident in the case of an interspersed minority subpopulation of tumor cells surrounded by an excess of normal cells, such as fibroblasts (5) .
With few exceptions the effects of a given normal cell population on the growth and behavior of a particular type of tumor have not been studied in the context of different stages of tumor progression. It is possible, for example, that the effect of normal adjacent cells on the growth of tumor cells from primary lesions early in tumor progression is quite different from the effects of more advanced (metastatically competent) primary lesions, or metastases. We recently uncovered an interesting example of this in the context of human malignant melanoma (6) . This type of cancer is one of the few where lesional steps in tumor progression are well defined and readily detectable (7) (8) (9) (10) . Thus, most primary melanomas arise in the epidermis as horizontal plaque-like lesions-the so-called "radial growth phase" (RGP) primary melanoma (7) . Despite invasion into the dermis, these melanomas are always curable by surgery and are thought to be composed of poorly proliferating tumor cells incompetent for metastasis (7) . The next stage is the vertical growth phase (VGP), in which the cells can grow as an expansile nodule in the dermal mesenchyme (7, 8) . This step initially encompasses lesions with little competence for metastasis (usually those with a thickness <0.76 mm, a low mitotic count, and a brisk lymphocytic infiltration) (11) and, subsequently, those likely to acquire metastatic competence (thick lesions with a high mitotic count and an absence of lymphocytic infiltration (11) . The latter lesions generally have phenotypic markers associated with metastatic melanoma cells-e.g., upregulation of intracellular adhesion molecule-1 and the j83 integrin subunit (12) (13) (14) . The final stage of melanoma progression is distant metastasis formation. We found that coculture of human melanoma cell lines with irradiated human dermal fibroblasts affected the growth of the melanoma cells as a direct function oftumor progression: cell lines derived from RGP or early-stage VGP primary tumors were growth inhibited, whereas a majority of cell lines from more advanced VGP primary or metastatic tumors were growth stimulated under the same conditions (6) . These results could be reproduced with fibroblast cell culture conditioned media, thus implicating the involvement of one or more secreted paracrine growth factors (6) .
From these results we speculated that a single growth factor may be involved that behaves as an inhibitor for early-stage melanoma cells but as a mitogenic agent for more advanced-stage melanoma cells. Alternatively, two different factors may be involved-one being an inhibitor, active only on early-stage melanoma cells, and the other being a stimulator, active only on the more advanced-stage melanoma Proc. Natl. Acad. Sci. USA 89 (1992) cells. Either possibility would provide metastatically competent melanoma cells with a relative growth advantage. In preliminary experiments we were unable to suppress the inhibitory or stimulatory influences of dermal fibroblasts on melanoma cell proliferation by addition of neutralizing antibodies to a number of known growth factors thought to be involved in the growth of solid tumors. These included transforming growth factor ( (TGF-(3), interferon a/3 and interferon y, basic fibroblast growth factor (bFGF), plateletderived growth factor, insulin-like growth factor-1, epidermal growth factor, and nerve growth factor (I. Cornil and R.S.K., unpublished observations). We therefore decided to identify the growth factor(s) involved by means of biochemical purification.
The purpose of the present report is to summarize our findings; they strongly implicate interleukin (IL)-6, a "hematopoietic" multifunctional cytokine, as the fibroblastderived growth inhibitor for early-stage melanoma cells. This raises the intriguing possibility that IL-6 could be a potential growth regulator of other types of nonhemopoietic human solid tumor, depending upon stage of disease progression. Growth Assays. These were done by using [3H]thymidine incorporation, essentially as described previously (6) . To monitor hFDGI activity during purification, appropriate amounts (50-200 Ad) of concentrated fibroblast-derived CM, or offractions from the chromatographic studies, were added to dialysis tubing with 1 mg of bovine serum albumin and dialyzed against 20 mM Tris-HCI buffer, pH 7.4, and subsequently against serum-free W489 medium. They were then sterilized through a 0.22-ium-pore filter and hFDGI bioactivity was assayed, using an early-stage (RGP) human melanoma cell line, WM35, as a growth-inhibition-sensitive "target." Human melanoma cells (5000 cells per well) were plated in 96-well plates and incubated with either hFDGI or cytokines for 36-48 hr. Cells were pulse labeled with [3H]thymidine for 4-6 hr before being harvested.
MATERIALS AND METHODS
To assess the effects of cytokines on melanoma cell growth, human cytokines prepared by recombinant DNA methods (Upstate Biotechnical, Lake Placid, NY) at various concentrations were added to cell cultures in ExCell 300 medium (J. R. Scientific; Woodland, CA) and 1% fetal bovine serum. Cytokines and their concentrations used were IL-la (0.5-50,000 pg/ml, 1 unit = 1 pg/ml), IL-1p (0.05-50.0 ng/ml, 1 unit = 0.1 ng/ml), IL-6 (0.025-250 ng/ml, 1 unit = 0.26 ng/ml), and tumor necrosis factor a (TNFa, 0.025-250 ng/ml, 2 x 108 units/mg). Highly specific polyclonal neutralizing antibodies to IL-6 (R & D Systems, Minneapolis) were used as described in Results. All experiments were repeated at least twice and conducted by triplicate determinations. Controls without added factors were considered as 100%.
Cell Lines. The origins of the melanoma cell lines used in these studies have been described in detail elsewhere by us (6) and by Herlyn and colleagues (9, 10, 15) . Some details are also summarized in Table 2 Fig. 1 and Table 1 , the threestep purification gave 0.5% total protein recovery and showed that hFDGI has a molecular mass of 20-30 kDa. The relative broad hFDGI activity peak in FPLC gel filtration (Fig. 1C) was reproducible by concentrated CM, indicating that the broad peak was not the result of acidic treatment of hFDGI in SP chromatography (data not shown). The semipurified hFDGI after FPLC was then tested on other human melanoma cell lines (Fig. 2 ). It will be noted that this semipurified material retained inhibitory activity against three of four early-stage melanoma cell lines (the exception being WM 793), whereas no effect was observed on the growth of a large number of more advanced stage (metastatically competent) melanoma cell lines, whether these were derived from VGP primary tumors or metastases. It also suppressed the growth of a melanoma cell line called WM 75 (data not shown), similar to dermal fibroblasts (6) . WM 75 behaves as a relatively early-stage VGP primary melanoma (D. Guerry, personal communication). In a previous paper we had mistakenly identified this cell line, which was called WM 75c, as having been derived from an advanced-stage metastasis (6) . The lack of any stimulatory activity on the advanced-stage cell lines implied the existence of a growth stimulator distinct from the inhibitor, which was lost during Association or Identity of hFDGI to IL-6. At this point several considerations prompted us to determine whether the inhibitory activity might be related to a particular member of the "hematopoietic" growth factor/cytokine family, namely IL-6. First, it is known that the molecular mass of IL-6 (19-30 kDa) is clearly in the same range as hFDGI, and it is also made by fibroblasts (16, 17) . The broad range in molecular masses is due to differential glycosylation of the polypeptide (16, 17) . Second, IL-6 has recently been shown (18) to inhibit the proliferation of normal human melanocytes (melanoma Table 2 and several references (6, 9, 10, 15 ). cells were not tested). Fig. 3 and Table 2 summarize the evidence which demonstrates that the fibroblast-derived inhibitory factor for early-stage melanoma cells is indeed most likely identical to IL-6. This evidence can be summarized as follows: (i) The addition of specific neutralizing antibodies to IL-6 abrogated the activity of hFDGI against the early-stage melanoma cell lines such as WM 35 (Fig. 3A). (ii) As shown in Table 2 and Fig. 3B , addition of human recombinant IL-6 to human melanoma cell line cultures resulted in growth inhibition ofthree offour early-stage melanoma cell lines, the exception being WM 793; WM 793 growth is likewise not inhibited by addition of hFDGI (Fig. 2) or by coculture with irradiated fibroblasts (6) . WM 75 cells were also inhibited (data not shown). In striking contrast, all of the more advanced stage-derived melanoma cell lines tested were found to be completely resistant to the inhibitory effects of exogenous IL-6 (Table 2 and Fig. 3B ), even at doses of 250 ng/ml, where some stimulation was observed (Fig. 3B ). It will be noted that IL-6 appears to be a very potent growth inhibitor (when it does inhibit) with concentrations in the 10-25 ng/ml range causing >90%o inhibition of DNA synthesis. It is also noteworthy that, with the exception of TNFa, there was a distinct trend towards sensitivity to the growth-inhibitory effects of several cytokines manifested by early-stage melanoma cell lines, which was lost in the more advanced-stagederived cell lines (Table 2) . Thus, two of four of the earlystage cell lines (WM 35 and WM 793) were inhibited by IL-la and IL-113, whereas none of the advanced-stage cell lines was inhibited. A similar trend towards increasing resistance with melanoma progression to exogenously added TGF-j3 has also been noted (J. MacDougall and R.S.K., unpublished results). Thus acquisition of resistance to a number of structurally diverse polypeptide growth inhibitors seems to be a feature of advanced-stage melanomas; this resistance is most consistently seen with IL-6. DISCUSSION IL-6 is generally viewed as a member of the hemopoietic growth factor/cytokine family (16, 17) . In terms of its capacity as a potential regulator of tumor cell growth, most studies have emphasized its possible role as a paracrine or autocrine stimulatory growth factor for various types of hematologic malignancies (19) 
were found to be insensitive to exogenously added IL-6. Our results, however, suggest otherwise, with the proviso that stage ofdisease be taken into consideration when assessing the possible influence of IL-6 on tumor cell growth. Thus the majority of melanoma cell lines from early (metastatically incompetent) stages of tumor progression were found to be highly sensitive to IL-6-mediated growth inhibition. This sensitivity was completely lost, however, in all the advancedstage (metastatically competent) melanomas that were examined.
The results with the metastatic cell lines are consistent with the results of Serve et al. (21) in that these authors used advanced-stage cancers. However, clearly, it cannot be concluded necessarily that IL-6 is an "inert" growth factor in the context of melanoma, and perhaps other types of solid tumor as well. This underscores the necessity of evaluating the response of tumor cells obtained from different stages of disease progression to a given growth factor when trying to determine the overall effect that factor has on tumor cell growth and behavior. Unfortunately, this has largely been ignored in most growth factor studies in human cancer, in part because it is frequently not possible to obtain early-stage lesions in most types of cancer, as it is in melanoma or colorectal carcinoma. The few studies that have been undertaken with this consideration in mind tend to support the view that increasing resistance to negative growth regulators such as TGF-p occurs with tumor progression (e.g., see refs. [22] [23] [24] . Since the tumor cells in many solid cancers have been found to express IL-6 activity in situ (25) , this suggests that in some cases IL-6 may not only cease being a paracrine growth inhibitor but may also actually behave as an "ectopic" stimulatory autocrine growth factor (26) . In this regard experiments are needed to evaluate the possible relationship of IL-6 production and IL-6 responsiveness in the melanoma cell lines studied in this report. Preliminary evidence indicates that cells from a number of advanced-stage melanoma cell lines do indeed make and that it functions as an autocrine growth stimulator in these cells (C.L. and R.S.K., unpublished observations). We have also recently undertaken Scatchard analyses of IL-6 receptor numbers and affinities in the melanoma cell lines studied here. No consistent differences were detected between early-and advancedstage-derived cell lines that could explain their disparate responses to IL-6 (C.L. and R.S.K., unpublished observations).
How might acquisition of an IL-6resistant phenotype affect the course of melanoma cell growth, progression, and metastasis? Loss of sensitivity to an inhibitor such as IL-6 represents a form of "progressive emancipation" from external negative growth control (5) , and this may endow rare metastatically competent melanoma cell variants with a growth advantage, thereby helping them eventually to overgrow their nonmetastatic counterparts within the primary tumor site (27, 28) . We have termed this process "clonal dominance" of primary tumors by metastatically competent tumor cell variants (27, 28) , a process that may enhance the probability of formation of distant metastases (29) . Human melanoma appears to conform to this type of evolutionary growth pattern (7, 10, 12, 14, 28) . Given the cellular ubiquity of IL-6-i.e., it is produced by keratinocytes, endothelial cells, fibroblasts, macrophages, and monocytes (16, 17) -it has considerable potential to facilitate the metastatic cell subpopulation clonal dominance process at the primary site, by impeding the growth of metastatically incompetent tumor cells. This may be particularly true in the dermal mesenchyme, where early-stage primary melanoma cells appear to have limited ability to proliferate, unlike their metastatically competent counterparts (7) . This process may be facilitated by the fact that human melanoma cells can release IL-1 (30, 31) , which is a major inducer of IL-6 expression (16, 17) . Thus there is the possibility of a closed paracrine IL-6/IL-1 loop involving host cells, such as endothelial cells or fibroblasts, and melanoma cells, which could limit the proliferative capacity of metastatically incompetent (i.e., IL-6-responsive) melanoma cells, in both the epidermis and the dermis. Finally, we point out that acquisition of resistance to the inhibitory effects of IL-6 by metastatically competent cancer cells may be accompanied by resistance to a number of other potential growth inhibitors, such as IL-la, IL-1,3, and TGF-P. This "multicytokine-resistant" phenotype (32) may be crucial to allowing metastatically competent melanoma cells to proliferate readily in the foreign environment of the dermal mesenchyme (where blood vessel capillaries are located and to which they can gain access) and perhaps distant organ mesenchymes as well (32) . These considerations also raise the intriguing notion that acquisition of resistance to one particular growth factor-e.g., TGF-j---may lead to expression of resistance to other structurally unrelated growth factors, such as IL-6-conceptually similar to the acquisition of multidrug resistance in cancer (32, 33) .
